SALIVARY DUCT CARCINOMA OF PAROTID GLAND- AN INCIDENTAL FINDING

*Suparna Suvernakar V¹, Shubha Deshpande A², Prabha Mulay S¹

¹Associate professor, ²Professor, Department of Pathology, Dr SC GMC Nanded, Maharashtra, India

*Corresponding author email: supi2020@gmail.com

ABSTRACT

Salivary duct carcinoma, a recently added separate entity of salivary gland tumor is a rare tumour with its aggressive behaviour. Due to morphological similarities with ductal carcinoma of breast the name salivary duct carcinoma is given. It is more common in male than in female. But our case is of 45yr female with mass in the parotid region. The diagnosis on USG and CT was organized collection. But on excision the diagnosis turned to be salivary duct carcinoma of the parotid gland

Keywords: Salivary gland, Salivary duct carcinoma, Incidental finding

INTRODUCTION

Salivary duct carcinoma is a rare tumor comprising about 1 to3% of malignant salivary gland tumours. It was first described by Klinsasser et al in 1968.¹ was not formally recognized in the World health organization classification on until 1991. Tumour is considered separately due to aggressive growth with regional or distant metastases.²⁴

CASE REPORT

A 45 yr female with tender swelling in left parotid region since 1 month. On examination globular swelling of 4x3cm, firm to hard and fixed to underlying structures. No lymph node was palpable. USG showed an organized collection in deep parotid. FNAC gave a diagnosis as a benign cystic lesion. CT finding suggestive of a collection of infective origin. Clinical diagnosis kept was parotid abscess. Then the swelling was excised, which was cystic multilobular 4x4 cm in deep lobe with adhesions. Histopathological examination showed ductal lesion containing tumour cells. Also seen tumour cells invading the stromal tissue.

Fig 1: Presence of duct lining with proliferation of epithelial lining with presence of duct lumen and central necrosis.

Fig 2: Section shows presence of tumor cells infiltrating in the stroma with desmoplastic reaction
DISCUSSION

It is a rare salivary gland tumour with similarity to comedo type of breast carcinoma hence named as salivary duct carcinoma. Represents 1 to 3% of all salivary gland tumours and 0.9 to 65 of all parotid tumours. It is a rapidly growing tumour. It frequently involves temporal bone via perineural spaces. Gingival metastases also occurs. Facial paralysis seen in 40 to 60% of cases and lymphadonopathy in 35% cases. It is common in males than in females with a range between 55 to 65 yrs. USG and CT finding are not specific. Positive diagnosis mainly depends upon the histopathological findings. Fine needle aspiration cytology is not always reliable. Gross finding shows tumour of variable size and predominant cystic component and at places invasive part seen. Intraductal component is papillary, solid, and cribriform with central necrosis. The infiltrative component is made of glands, cords of cells with desmoplastic reaction. Several variants are described such as sarcomatoid, low grade neoplasm and mucin rich neoplasm. Immunohistochemical finding are not useful but a constant over expression of keratin HER-2/new, CEA and c-erd-B2 have been described. The differential diagnosis includes, mucoepidermoid carcinoma, adenocarcinoma not otherwise specified, Metastatic adenocarcinoma, oncocytic carcinoma, and the most relevant morphological feature is the presence of an intraductal component which is specific for the diagnosis. Therapeutic approach seems to be non-consensual because of the limited data, but many other authors recommend, in parotid gland tumors, a total parotidectomy even in T1 tumors because local disease recurrence is often life threatening. If facial paralysis is present, a radical parotidecotomy is mandatory. Postoperative radiation therapy is indicated in case of extra parotid extension, pathological resection margins, cervical lymph node involvement, lymphatic embolus and neurologic invasion. Chemotherapy is generally reserved for distant metastases.

CONCLUSION

Salivary duct carcinoma is an aggressive tumour with worst prognosis because of its metastatic potential. Nearly 50% die within 4 to 5 years. The diagnosis may be missed on FNAC, USG, CT due to large areas of necrosis. Histopathological examination is a simple and confirmative.

Conflict of interest: Nil

REFERENCES


